Omnicell Inc (OMCL) - Total Liabilities
Based on the latest financial reports, Omnicell Inc (OMCL) has total liabilities worth $742.91 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Omnicell Inc - Total Liabilities Trend (2000–2025)
This chart illustrates how Omnicell Inc's total liabilities have evolved over time, based on quarterly financial data. See OMCL current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Omnicell Inc Competitors by Total Liabilities
The table below lists competitors of Omnicell Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Streamax Technology Co Ltd
SHE:002970
|
China | CN¥1.49 Billion |
|
China Cinda Asset Management Co., Ltd.
F:0CI
|
Germany | €1.50 Trillion |
|
Shenzhen Ysstech Info-Tech Co Ltd
SHE:300377
|
China | CN¥212.98 Million |
|
Shenzhen Changhong Tech
SHE:300151
|
China | CN¥1.04 Billion |
|
Jiangsu Linyang Energy Co Ltd
SHG:601222
|
China | CN¥8.84 Billion |
|
Gorman-Rupp Company
NYSE:GRC
|
USA | $445.33 Million |
|
Gansu Qilianshan Cement Group Co Ltd
SHG:600720
|
China | CN¥13.31 Billion |
|
Spectrum Brands Holdings Inc
NYSE:SPB
|
USA | $1.52 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Omnicell Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Omnicell Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Omnicell Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Omnicell Inc (2000–2025)
The table below shows the annual total liabilities of Omnicell Inc from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $742.91 Million | -15.35% |
| 2024-12-31 | $877.65 Million | -15.44% |
| 2023-12-31 | $1.04 Billion | -3.95% |
| 2022-12-31 | $1.08 Billion | +8.52% |
| 2021-12-31 | $995.81 Million | +16.20% |
| 2020-12-31 | $857.00 Million | +116.66% |
| 2019-12-31 | $395.56 Million | -1.51% |
| 2018-12-31 | $401.62 Million | -13.28% |
| 2017-12-31 | $463.11 Million | -8.02% |
| 2016-12-31 | $503.50 Million | +185.49% |
| 2015-12-31 | $176.36 Million | +3.67% |
| 2014-12-31 | $170.12 Million | +18.00% |
| 2013-12-31 | $144.17 Million | +5.89% |
| 2012-12-31 | $136.15 Million | +72.22% |
| 2011-12-31 | $79.05 Million | +1.60% |
| 2010-12-31 | $77.81 Million | -1.55% |
| 2009-12-31 | $79.03 Million | +4.63% |
| 2008-12-31 | $75.53 Million | +2.37% |
| 2007-12-31 | $73.78 Million | +14.16% |
| 2006-12-31 | $64.63 Million | +43.03% |
| 2005-12-31 | $45.19 Million | -1.32% |
| 2004-12-31 | $45.79 Million | -7.88% |
| 2003-12-31 | $49.71 Million | +0.96% |
| 2002-12-31 | $49.24 Million | -6.24% |
| 2001-12-31 | $52.51 Million | -23.82% |
| 2000-12-31 | $68.93 Million | -- |
About Omnicell Inc
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for th… Read more